Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ROS1 is a receptor tyrosine kinase involved in epithelial cell differentiation and regionalization. Somatic rearrangements leading to fusion proteins containing the ROS1 kinase domain are oncogenic drivers, particularly in non-small cell lung cancer. These fusions activate downstream signaling pathways like RAS-MAPK, PI3K-AKT-mTOR, and JAK-STAT3, promoting cell growth, proliferation, and survival. PD-L1 upregulation following ROS1 fusion activation is relevant for immunotherapy.
Tyrosine kinase inhibition
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on C-ros oncogene 1, receptor tyrosine kinase (ROS1).